2043 results about "Globulin" patented technology

The invention discloses a monoclonal antibody for distinguishing a hog cholera lapinized virus vaccine strain and a hog cholera lapinized virus epidemic strain and application of the monoclonal antibody, and belongs to the field of immune globulin. The E2 protein monoclonal antibody or the antigen binding fragment thereof comprises a heavy chain variable region (SEQ ID No.1) and a light chain variable region (SEQ ID No.3). The invention also discloses an ELISA method for identifying and distinguishing hog cholera lapinized virus vaccine strains and epidemic strains by using the E2 protein monoclonal antibody. The monoclonal antibody disclosed by the invention has a specific reaction with the swine fever virus epidemic strain and does not react with the swine fever lapinized virus vaccine strain, and the swine fever lapinized virus vaccine strain and the epidemic strain can be accurately identified and distinguished by utilizing an ELISA competition method established by the monoclonal antibody. The monoclonal antibody provided by the invention can be used in the fields of CSFV immunization, serological diagnosis of wild viruses, immune effect evaluation, related experiments and the like, and provides antibody resources for effective detection and purification of CSFV.

Provided herein are novel immunoglobulin G (IgG) proteases and fusion proteins comprising the same. The IgG proteases find utility in methods of treating diseases mediated in whole or in part by pathogenic immunoglobulin G (IgG) antibodies, including methods for preventing or treating antibody-mediated rejection (AMR) of an organ allograft in an organ-transplant patient.

The invention discloses an anti-pestivirus broad-spectrum neutralizing monoclonal antibody and application thereof, and belongs to the field of immune globulin. The anti-pestivirus monoclonal antibody or the antigen binding fragment thereof comprises a heavy chain variable region (SEQ ID No.1) and a light chain variable region (SEQ ID No.3). The monoclonal antibody provided by the invention can identify hog cholera virus and all known plague virus members (BVDV1, BVDV2, BDV, HoBiPeV, AydinPeV and OVPV) capable of infecting cattle and sheep at present, has good neutralizing ability, and can be prepared into a diagnostic product for plague virus antigen-antibody detection. The monoclonal antibody and a diagnostic product developed based on the monoclonal antibody can be used for serological diagnosis and immune effect evaluation of pestivirus, pestivirus pathogen detection of experimental serum products and the like, and have wide application prospects in the fields of clinical diagnosis and the like.

The invention discloses a bran coat polypeptide GR-12 with an immunoregulation function and an application of the bran coat polypeptide GR-12, and the amino acid sequence of the bran coat polypeptide is Gly-Gln-Pro-Trp-Pro-Pro-Ala-Ser-Phe-Ala-Cys-Arg (GQPWPPASFACR, which is called GR-12 for short). Experiments find that the GR-12 can significantly enhance the proliferation activity and phagocytic activity of macrophages RAW264.7 and promote the macrophages RAW264.7 to secrete cytokines; meanwhile, it is found that the GR-12 can significantly enhance the immunomodulatory function of an immunosuppressive mouse induced by cyclophosphamide, specifically, the body weight, thymus index and spleen index of the immunosuppressive mouse are significantly recovered; and the secretion of cytokines and immune globulins in mouse serum is obviously increased. The bran coat polypeptide GR-12 is expected to be further researched and developed into a related medicine product with an immune regulation function, and has a wide application prospect.

The invention discloses a patient immune response monitoring method and system for cell drug clinical research, and the method comprises the following steps: 1, obtaining a peripheral blood sample of a patient, and preprocessing the peripheral blood sample to obtain patient sample components; multi-dimensional immune indexes and cell drug specific immune response are detected by comprehensively utilizing multiple technologies, immune cell subsets, cell factors, immune globulin, T cell response and the like are covered, and therefore a complex immune response system is comprehensively reflected; peripheral blood samples are collected at multiple time points according to a cell drug action mechanism and a half-life period, and the whole-course change of the immunoreaction is effectively tracked, so that the development trend of the immunoreaction is accurately grasped; the method has the advantages that the characteristics are visually presented by constructing the immune response atlas of the patient, evaluation and prediction are assisted, real-time monitoring reports and treatment suggestions are provided according to evaluation and prediction results, doctors are assisted to adjust treatment in time, and accordingly the safety and effectiveness of cell drug treatment are improved.

The invention provides a molecular marker related to immune traits of elephant male semi-fine wool sheep and a detection primer and application thereof, and belongs to the technical field of molecular assisted breeding. The nucleotide sequence of the molecular marker is shown as SEQ ID NO.1; the molecular marker comprises an SNP site, the SNP site is located at the 117th site of the molecular marker, the mutation basic group of the SNP site is A or G, and the immune globulin content of an individual male semi-fine wool sheep with the genotype of AG or GG at the SNP site is remarkably higher than that of an individual with the genotype of AA. The content of immune globulins IgA, IgG and IgM of an individual elephant male semi-fine-wool sheep can be judged according to the genotype of the molecular marker, the immune traits of the elephant male semi-fine-wool sheep can be rapidly and accurately evaluated, the high-immunity elephant male semi-fine-wool sheep can be screened, the molecular marker has important significance on early-stage auxiliary breeding of the elephant male semi-fine-wool sheep, the breeding period is remarkably shortened, and the breeding cost is reduced. The breeding efficiency is improved.

The present disclosure relates to proteases that exhibit activity against immunoglobulins, particularly IgM antibodies, and uses of the proteases for analysis of IgM, for generation of IgM antibody fragments, diagnostics related to IgM antibodies, and for treating and / or preventing diseases mediated by IgM antibodies.

The present invention relates to immunoglobulins, such as immunoconjugates, comprising an ActRII receptor antibody and an agonistic GLP-1 molecule, such as agonistic GLP-1 peptide. Such constructs are useful in the treatment of numerous diseases and disorders, including metabolic disorders, such as obesity, diabetes and others.

The invention belongs to the field of biological medicine, and particularly relates to a respiratory syncytial virus F protein mutant and application thereof. The respiratory syncytial virus F protein mutant is characterized in that at least one pair of amino acid residues in an F1 subunit and / or an F2 subunit of F protein polypeptide are substituted by cysteine, and / or an F protein signal peptide part is substituted by a human immunoglobulin light chain signal peptide, and / or alanine A at the 107 site of a multi-base sequence is mutated into arginine R, lysine K at the 134 site is mutated into arginine R, and the amino acid residues in the F1 subunit and / or the F2 subunit of the F protein polypeptide are mutated into arginine. According to the invention, more neutralizing antibody epitopes can be exposed, the stable pre-fusion conformation is maintained, effective neutralizing antibody reaction and antibody binding reaction to the RSV subtypes A and B can be ensured, and the vaccine is suitable for various vaccine forms taking the RSV F protein as the antigen.

The invention belongs to the technical field of immunodetection, and discloses a rabbit monoclonal antibody mAb6 of an anti-mouse immune globulin G2a subtype (IgG2a) and application thereof. The rabbit monoclonal antibody mAb6 comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises LCDR1-3, the LCDR1 comprises an amino acid sequence KSVYKNNY, the LCDR2 comprises an amino acid sequence GTN, and the LCDR3 comprises an amino acid sequence AGGYID; the heavy chain variable region comprises HCDR1-3, the HCDR1 comprises an amino acid sequence RFSLSNYR, the HCDR2 comprises an amino acid sequence IFTRGST, and the HCDR3 comprises an amino acid sequence ARGWNS. The rabbit monoclonal antibody disclosed by the invention can be combined with a mouse immune globulin G2a subtype (IgG2a) in a high-specificity manner, can be applied to immunodetection, and provides a basis for further preparation of engineering antibodies.

The invention provides a molecular marker related to immune traits of elephant male semi-fine wool sheep and application of the molecular marker, and belongs to the technical field of molecular marker application, and the nucleotide sequence of the molecular marker is shown as SEQ ID NO.1; the molecular marker comprises an SNP site, the SNP site is located at the 363rd site of the molecular marker, the basic group of the SNP site is T or C, and the immune globulin content of a male semi-fine wool sheep individual with the genotype of TC or CC at the SNP site is remarkably higher than that of a male semi-fine wool sheep individual with the genotype of TT. By detecting the genotype of the molecular marker SNP site related to the immune traits in the male semi-fine-wool sheep, the immune traits of the male semi-fine-wool sheep can be rapidly and accurately evaluated, and the molecular marker SNP site has important significance on early-stage auxiliary breeding of the male semi-fine-wool sheep.

The invention relates to the technical field of nutritional supplements. A traditional fat reducing method mainly comprises dieting, high-intensity exercise, medicine weight losing and the like. However, dieting may lead to malnutrition; high-intensity sports are difficult to insist, and sports injury is easily caused; in order to solve the technical problems, the invention discloses a fat-reducing nutritional composition capable of improving metabolism, and the fat-reducing nutritional composition can be used for solving the technical problems of severe side effects such as tachycardia, insomnia and the like caused by medicine weight loss. The composition comprises the following components in parts by weight: 13-21 parts of a bitter gourd extract, 15-31 parts of a garcinia cambogia extract, 13-17 parts of oat fibers, 17-23 parts of whey protein powder, 7-9 parts of linseed oil, 6-14 parts of a green tea extract, 9-15 parts of a calcium supplement and 15-19 parts of a purple perilla seed extract, and can provide energy for a user, supplement immune globulin, lactoferrin and a calcium source, improve the immunity of the user and improve the immunity of the user. The body metabolism level and immunocompetence are improved, absorption of fat in digestive tracts can be effectively inhibited, storage of fat in the body is reduced, fat consumption is promoted, and the fat reducing effect is achieved.

The invention provides a preparation method of antitoxin serum containing an horse F (ab ') 2 fragment, and the specific steps are as follows: a recombinant streptococcus immunoglobulin G degrading enzyme is immobilized to obtain an immobilized enzyme chromatography column, the recombinant streptococcus immunoglobulin G degrading enzyme comprises a glutathione-S-transferase tag and a histidine tag; performing primary treatment on the immune plasma to obtain a pretreated antibody solution; the pretreatment antibody solution is added into an immobilized enzyme chromatography column for digestion, after digestion is completed, ultrafiltration, purification and solution preparation are sequentially conducted through an immobilized glutathione affinity column or a nickel affinity column, an antitoxin serum stock solution is obtained, and the antitoxin serum stock solution contains F (ab ') 2 fragments and does not contain Fc fragments, impure protein and small molecule impurities. Through the process steps, the Fc fragment and impure protein are effectively removed, and only the horse F (ab ') 2 fragment is reserved, so that the immunogenicity of antitoxin serum and the risk of causing anaphylactic reaction are remarkably reduced.

The present invention relates to bispecific antigen binding molecules specific for both the receptor tyrosine kinase-like orphan receptor 1 (ROR1) and the epidermal growth factor receptor (EGFR), as well as related fusion proteins and conjugates. In another aspect, the invention relates to conjugated immunoglobulin-like shark variable neoantigen receptors (VNARs).

The invention discloses lactobacillus gasseri capable of improving expression of host antibacterial peptide Cathelicidin and secretory immunoglobulin sIgA and enhancing infection resistance by oral administration and external application and a metagen thereof, and belongs to the technical field of microorganisms. The lactobacillus gasseri disclosed by the invention can be used for promoting the generation of a vaginal epithelial cell antibacterial peptide Cathelicidin; the shedding of vaginal epithelial cells is reduced, the fungal load is reduced, and the generation of vaginal tissue antibacterial peptide CRAMP is improved; the pIgR and immune globulin content of the vaginal tissue is increased; the invention also finds that the lactobacillus gasseri for external use can regulate and control TLR2 (Toll-Like Receptor 2), and further has a good balancing effect on body immunity. Therefore, the lactobacillus gasseri has a huge application prospect in a product for improving the pathogenic bacterium infection resistance of a host, enhancing the self-defense capability and inhibiting the vagina inflammation.

The invention provides universal functional formula milk powder for cats and dogs and a preparation method thereof, and relates to the field of pet formula food. The formula milk powder consists of goat milk powder, colostrum powder, whey protein powder, lactoferrin powder, yolk powder, immune globulin powder, compound grease, compound minerals, compound vitamins, choline, taurine, compound prebiotics, compound probiotics, docosahexaenoic acid, arachidonic acid, casein phosphopeptides, L-glutamine and beta-galactosidase. And the goat milk powder, colostrum powder, whey protein powder, lactoferrin powder, yolk powder and immune globulin powder are subjected to low-temperature sterilization treatment by adopting an induced electric field or high-pressure microjet. The cat and dog formula milk powder overcomes the defects in the prior art, through compounding of basic nutritional ingredients and functional ingredients, a novel low-temperature sterilization technology is adopted for sterilization treatment, on the premise that the functionality of the formula milk powder is guaranteed, the nutritional value of the formula milk powder is reserved to a greater extent, and healthy growth and development of cats and dogs are promoted.

The invention provides an egg yolk globulin powder processing traceability method and system, and the method comprises the steps: carrying out the multi-node monitoring of each processing traceability process through a block chain technology, and carrying out the chain packaging of a processing dependency relationship between adjacent processing traceability processes and a time certificate provided by an authority timestamp service; generating a chained association block between adjacent processing nodes in each processing traceability process; performing digital signature on the initial identification code of the egg yolk globulin powder raw material, the processing node information of each processing traceability process and the combined data of the preorder data block hash value, and generating a credible voucher of each processing traceability process; jointly constructing a traceability node of each processing traceability process based on the credible voucher of each processing traceability process, the processing node information and the chained association block; and generating a tamper-resistant full-process tracing chain of the egg yolk globulin powder based on each tracing node. Based on the scheme, cross-link credible association in egg yolk globulin powder processing traceability can be realized.

The present invention relates to the field of tumor treatment and immunology biology. Provided are a pharmaceutical combination containing an anti-PD-1-anti-VEGFA bispecific antibody, and the use thereof. Specifically, the pharmaceutical combination comprises at least one bispecific antibody and at least one PARP inhibitor, wherein the bispecific antibody comprises a first protein functional region for targeting PD-1 and a second protein functional region for targeting VEGFA; and according to the EU numbering system, the heavy chain constant region of an immunoglobulin contained in the bispecific antibody is mutated at two sites, i.e. site 234 and site 235, and after mutation, the affinity constant of the bispecific antibody to FcγRI, FcγRIIa, FcγRIIIa and / or C1q is reduced compared with the affinity constant of the bispecific antibody thereto before mutation. The combined administration of the PARPi and the bispecific antibody has a significantly better therapeutic effect on tumors than the individual use of the PARPi or the bispecific antibody; and the present invention has good application prospects.

The invention belongs to the technical field of immunodetection, and discloses a specific monoclonal antibody mAb48 of rabbit anti-human immunoglobulin G2 subtype (IgG2), the specific monoclonal antibody mAb48 comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises LCDR1-3, the LCDR1 comprises an amino acid sequence EDIGYG, the LCDR2 comprises an amino acid sequence GAS, and the LCDR3 comprises an amino acid sequence QQGFS; the heavy chain variable region comprises HCDR1-3, the HCDR1 comprises an amino acid sequence GFSLSNYE, the HCDR2 comprises an amino acid sequence ISSSGST, and the HCDR3 comprises an amino acid sequence ARNNNN. The monoclonal antibody disclosed by the invention can be combined with human immune globulin G2 subtype (IgG2) in a high-specificity manner, can be applied to immunodetection, and provides a basis for the preparation of engineering antibodies in the next step.

Methods and compositions for treating fibrosis (e.g., cardiac fibrosis), or other conditions associated with inflammation and / or fibrosis are provided. Methods can include administering a nucleic acid encoding a sialic acid-binding immunoglobulin-type lectin 9 (Siglec-9) protein to a subject in need of fibrosis treatment, where the Siglec-9 protein is expressed by the nucleic acid in regulatory T (Treg) cells in the subject. Methods and compositions can include Treg cells that overexpress Siglec-9 to enhance the ability of Treg cells to target cells expressing amine oxidase, copper containing 3 (AOC3), including fibroblasts or myofibroblasts. In some embodiments, the enhanced Treg cells are targeted to myofibroblasts (e.g., cardiac myofibroblasts) with elevated expression of fibrotic genes.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention provides an application of a T lymphatic activation related cytokine as a biomarker in prediction of children immune globulin non-reactive Kawasaki disease. The team finds that in patients of an IVIG sensitive group and an IVIG non-response group, differences of expression levels of IL-6 and IL-17 before and after treatment have statistical significance; meanwhile, ROC curve analysis shows that IL-6 and IL-17 serve as early warning signals, and the prediction efficiency of the IVIG-unreacted Kawasaki disease is remarkably superior to that of existing prediction factors. Particularly, the levels of IL-6 and IL-17 are re-evaluated after initial treatment, so that the early prediction accuracy of the IVIG unresponsive Kawasaki disease can be further improved. By introducing IL-6 and IL-17 as novel biomarkers, early accurate prediction of the IVIG unresponsive Kawasaki disease is realized. Compared with the prior art, the method can provide a quicker and more accurate risk assessment basis for clinicians, so that early recognition of high-risk patients, optimization of subsequent treatment schemes and reduction of serious complications are facilitated, and a new thought and direction are provided for clinical diagnosis and treatment.

The invention relates to the technical field of microorganisms, and discloses a lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 and an application thereof in improving an immune function, the lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.30047, and the preservation time is March 18, 2024. The lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 can be used for directly improving the immune function of an immunosuppressive mouse by protecting and maintaining normal physiological structures of central and peripheral immune organs and promoting secretion of serum cytokines and immune globulins; and the immune function of the mouse can be indirectly promoted by relieving intestinal inflammation reaction.

Chimeric antigen receptors that include an antigen recognition domain; a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR; and an intracellular signaling domain.

The invention relates to a biomarker combination for clinical benefit of non-small cell lung cancer immunotherapy and application of the biomarker combination. The biomarker for predicting the clinical benefit of the non-small cell lung cancer immunotherapy comprises an immune globulin kappa light chain variable region 1-27 (IGKV1-27), a human leukocyte antigen H (HLA-H), an S100 calcium binding protein A8 (S100A8), a chromogranin A (CHGA), an elastin (ELN) and a nephronectin (NPNT). The biomarkers for predicting the clinical benefit of the immunotherapy of the non-small cell lung cancer can be detected, and the clinical benefit effect of the immunotherapy of the non-small cell lung cancer of a patient is judged by the markers.

The invention relates to a bifunctional protein targeting PD-1 and TGF [beta] and application of the bifunctional protein in cancer treatment by combining radiotherapy. Specifically, the present invention relates to the use of a bifunctional protein targeting PD-1 and TGF [beta] in the preparation of a medicament for treating an individual suffering from cancer, the bifunctional protein targeting PD-1 and TGF [beta] comprising: (1) an anti-PD-1 antibody or an antigen binding fragment thereof; (2) an immunoglobulin Fc structural domain; and (3) a TGF-beta R II extracellular domain. The invention further relates to application of the PD-1 and TGF beta targeting bifunctional protein in preparation of drugs for treating or preventing lung diseases or symptoms, especially radiation-induced lung injury, caused by radiotherapy of individuals.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention relates method of treatment of cancer using novel bispecific antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47 and the second is specific for mesothelin (MSLN). In addition, the disclosure contains methods of treatment using novel bispecific antibodies in combination with anti-PD-1 antibody.

The present invention belongs to the technical field of monoclonal antibody preparation, and specifically relates to a method for preparing a universal whole-pig monoclonal antibody. The present invention is based on single B cell antibody preparation technology, and antigen-specific single B lymphocytes are separated from the peripheral blood of immune pigs or clinically recovered pigs by flow cytometry sorting technology; according to the pig immunoglobulin IgG antibody gene sequence in the database, primers are designed to specifically amplify the complete coding genes of antibody heavy and light chains in pig single B cells and add His tags, and pCDNA3.1-Leader is used as a eukaryotic expression vector to construct a recombinant vector of complete coding genes for antibody light and heavy chains, and natural whole-pig monoclonal antibodies are expressed by mammalian cells. The present invention establishes a universal whole-pig monoclonal antibody preparation method for the first time, which can be used for the preparation and screening of pig monoclonal antibody libraries of different pathogens. Compared with other antibody preparation methods, it has the advantages of high throughput, whole pig source, good diversity, complete antibodies and natural pairing, etc., which provides technical support for the rapid preparation and screening of pig monoclonal antibodies and has broad application prospects.

The invention discloses a composite microecological preparation as well as a preparation method and application thereof. The compound microecological preparation disclosed by the invention comprises lactobacillus casei, lactobacillus plantarum and saccharomyces cerevisiae. The application effect of the composite microecological preparation in cow breeding is remarkable, the optimal addition amount of the composite microecological preparation is 100 mL / cow / day, the production performance of lactating cows can be improved, the milk yield is improved by 3.30 kg / cow / day, the milk yield of 4% standard milk is improved by 3.78 kg / cow / day, the total protein is improved by 15.9%, the albumin is improved by 14.7%, the globulin is improved by 16.5%, and the somatic cell number is reduced by 52.6%; and pollutant emission can be reduced, including 37.2% of ammonia emission reduction and 28.7% of carbon dioxide emission reduction.